• 1
    Handin RJ. Disorders of the platelet and vessel wall. In: KasperDL, BraunwaldE, HauserSL, FauciAS, JamesonJL, LongoDL, eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill Medical Publishing Division, 2004: 67380.
  • 2
    Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. Gut 1999; 45: 111.
  • 3
    Strader DB, Wright T, Thomas DL, Seeff LB. American association for the study of liver diseases. diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771 [Erratum in: Hepatology 2004; 40: 269].
  • 4
    Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18: 15367.
  • 5
    Gallus AS, Lucas CR, Hirsch J. Coagulation studies in patients with acute infectious hepatitis. Br J Haematol 1972; 22: 76171.
  • 6
    Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000; 95: 29369.
    Direct Link:
  • 7
    Giannini E, Botta F, Borro P, et al. Platelet count spleen/diameter ratio: proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52: 12005.
  • 8
    Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Sem Liv Dis 2002; 22: 8396.
  • 9
    Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994; 21: 65666.
  • 10
    Liangpunsakul S, Ulmer BJ, Chalasani N. Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci 2003; 326: 1116.
  • 11
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 42130.
  • 12
    Caturelli E, Bartolucci F, Biasini E, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97: 397405.
    Direct Link:
  • 13
    Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39: 20814.
  • 14
    Heathcote EJ. Treatment consideration in patients with hepatitis C and cirrhosis. J Clin Gastroenterol 2003; 37: 3958.
  • 15
    Schmid M, Kreil A, Jessner W, et al. Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut 2005; 54: 101420.
  • 16
    Heathcote EJ, Shiffman ML, Cooksley WGE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343; 167380.
  • 17
    Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 14249.
  • 18
    Chu CW, Hwang SJ, Lu RH, et al. Clinical significance of the changes of platelet counts and serum thrombopoietin levels in chronic hepatitis C patients treated with different doses of consensus interferon. Hepatol Res 2002; 24: 23644.
  • 19
    Crippin JS, McCashland T, Terrault N, Sheiner P, Michale R, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 3505.
  • 20
    Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000; 14 (Suppl. D): 606.
  • 21
    Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of ‘‘hypersplenic’’ thrombocytopenia. J Clin Invest 1966; 45: 64557.
  • 22
    Ballard HS. Hematological complications of alcoholism. Alcohol Clin Exp Res 1989; 13: 70620.
  • 23
    Bordin G, Ballare M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995; 13 (Suppl. 13): S3943.
  • 24
    Nagamine T, Ohtuka T, Takehara K, Arai T, Takagi H, Mori M. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996; 24: 13540.
  • 25
    Pockros PJ, Duchini A, McMillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 97: 20405.
    Direct Link:
  • 26
    Ierardi E, Rendina M, Francavilla R, et al. Mycophenolate mofetil in the treatment of autoimmune HCV-associated haematological disorders showing steroid resistance or dependence. J Viral Hepat 2003; 10: 3903.
  • 27
    Mutchnik MG, Lerner E, Conn HO. Effect of portacaval anastomosis on hypersplenism. Dig Dis Sci 1980; 25: 92938.
  • 28
    Jabbour N, Zajiko A, Orons P, Irish W, Fung JJ, Selby RR. Does transjugular intrahepatic portosystemic shunt (TIPS) resolve thrombocytopenia associated with cirrhosis? Dig Dis Sci 1998; 43: 245962.
  • 29
    Karasu Z, Gurakar A, Kerwin B, et al. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 2000; 45: 19716 [Erratum in: Dig Dis Sci 2001; 46: 449].
  • 30
    Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994; 91: 111048.
  • 31
    de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 5338.
  • 32
    Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 5658.
  • 33
    Wendling F, Maraskovsky E, Debili N, et al. CMpl is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 5714.
  • 34
    Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is ligand for the cytokine receptor Mpl. Cell 1994; 77: 111724.
  • 35
    Sohma Y, Akahori H, Seki N, et al. Molecular cloning and chromosomal localisation of the human thrombopoietin gene. FEBS Lett 1994; 353: 5761.
  • 36
    Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukaemia virus immortalizes hematopoietic progenitors. Cell 1990; 63: 113747.
  • 37
    Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995; 74: 5215.
  • 38
    Eaton DL, de Sauvage EJ. Thrombopoietin. The primary regulator of megakaryocytopoiesis and thrombopoieis. Exp Hematol 1997; 25: 17.
  • 39
    Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339: 74654.
  • 40
    Kuter DJ. Thrombopoietin: biology and clinical applications. Oncologist 1996; 1: 98106.
  • 41
    Martin TG, Shuman MA. Interferon-induced thrombocytopenia. Is it time for thrombopoietin? Hepatology 1998; 28: 14302.
  • 42
    Pavithran K, Doval C. Thrombopoietin – biology and clinical applications. Oncol Forum 2001; 5: 204.
  • 43
    Nichol JL. Endogenous TPO (eTPO) level in health and disease: possible clues for therapeutic intervention. Stem Cells 1998; 16 (Suppl. 2): 16575.
  • 44
    Qian S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 1998; 92: 218991.
  • 45
    Nomura S, Ogami K, Kawamura K, et al. Cellular localization of thrombopoietin mRNA in the liver by in situ hybridisation. Exp Hematol 1997; 25: 56572.
  • 46
    Ishikawa T, Ichida T, Matsuda Y, et al. Expression of hepatic thrombopoietin mRNA in primary cultured hepatocytes and in rats with acute liver injury or bone marrow suppression with or without cirrhosis. J Gastroenterol Hepatol 2000; 15: 64753.
  • 47
    Jelkmann W. The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol 2001; 13: 791801.
  • 48
    Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002; 17: 610.
  • 49
    Peck-Radosavljevic M, Zacherl J, Meng YG, et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver? J Hepatol 1997; 27: 12731.
  • 50
    Martin TG, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997; 127: 2858.
  • 51
    Peck-Radosavljevic M, Zacherl J, Wichlas M, et al. Thrombopoietic cytokines and reversal of thrombocytopenia after liver transplantation. Eur J Gasteronterol Hepatol 1999; 11: 1516.
  • 52
    Goulis J, Chau TN, Jordan S, et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999; 44: 7548.
  • 53
    Kawasaki T, Takeshita A, Souda K, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999; 94: 191822.
    Direct Link:
  • 54
    Español I, Gallego A, Enríquez J, et al. Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. Hepatogastroenterology 2000; 47: 14046.
  • 55
    Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95: 795801.
  • 56
    Okubo M, Shiota G, Kawasaki H. Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond) 2000; 99: 20714.
  • 57
    Giannini E, Borro P, Botta F, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 2002; 37: 5727.
  • 58
    Giannini E, Botta F, Borro P, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003; 98: 251620.
    Direct Link:
  • 59
    Stockelberg D, Andersson P-O, Björnson E, Björk S, Wadenvik H. Plasma thrombopoietin levels in liver cirrhosis and kidney failure. J Internal Med 1999; 246: 4715.
  • 60
    Aref S, Mabed M, Selim T, Goda T, Khafagy N. Thrombopoietin (TPO) levels in hepatic patients with thrombocytopenia. Hematology 2004; 9: 3516.
  • 61
    Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005; 100: 13116.
    Direct Link:
  • 62
    Koruk M, Onuk MD, Akcay F, Savas MC. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology 2002; 49: 16458.
  • 63
    Schoffski P, Tacke F, Trautwein C, et al. Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. Liver 2002; 22: 11420.
  • 64
    Ishikawa T, Ichida T, Sugahara S, et al. Thrombopoietin receptor (c-Mpl) is constitutively expressed on platelets of patients with liver cirrhosis, and correlates with its disease progression. Hepatol Res 2002; 23: 11521.
  • 65
    Vyzantiadis T, Theodoridou S, Giouleme O, et al. Serum thrombopoietin levels in thrombocytopenic patients with liver cirrhosis. Haematologica 2002; 87: 8901.
  • 66
    Hidaka H, Kokubu S, Saigenji K, Isobe Y, Maeda T. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res 2002; 23: 26573.
  • 67
    Demetri GD. Pharmacologic treatment options in patients with thrombocytopenia. Semin Hematol 2000; 37 (Suppl. 4): 118.
  • 68
    Begley CG, Basser RL. Biologic and structural differences of thrombopoietic growth factors. Semin Hematol 2000; 37 (Suppl. 4): 1927.
  • 69
    Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336: 4049.
  • 70
    Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 127981.
  • 71
    Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997; 126: 67381.
  • 72
    Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132: 3648.
  • 73
    Vadhan-Raj S, Cohen V, Bueso-Ramos C. Thrombopoietin growth factors and cytokines. Curr Hematol Rep 2005; 4: 13744.
  • 74
    Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 32418.
  • 75
    Kuter JD. Whatever happened to thrombopoietin? Transfusion 2002; 42: 27983.
  • 76
    Kaushansky K. Hematopoietic growth factor mimetics. Ann N Y Acad Sci 2001; 938: 1318.
  • 77
    Dower WJ, Cwirla SE, Balasubramanian P, Schatz PJ, Baccanari DP, Barrett RW. Peptide agonists of the thrombopoietin receptor. Stem Cells 1998; 16 (Suppl. 2): 219.
  • 78
    de Serres M, Ellis B, Dillberger JE, et al. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man. Stem Cells 1999; 17: 2039.
  • 79
    de Serres M, Yeager RL, Dillberger JE, et al. Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration. Stem Cells 1999; 17: 3166.
  • 80
    Case BC, Hauck ML, Yeager RL, et al. The pharmacokinetics and pharamacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large-animal model of chemotherapy-induced thrombocytopenia. Stem Cells 2000; 18: 3605.
  • 81
    Inagaki K, Oda T, Naka Y, Shinkai H, Komatsu N, Iwamura H. Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities. Blood 2004; 104: 5864.
  • 82
    Neben TY, Leobelenz J, Hayes L, et al. Recombinant human interleukin-11 stimulates megakaryopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993; 81: 9018.
  • 83
    Tepler I, Elias L, Smith II JW, et al. A randomised placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87: 360714.
  • 84
    Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87: 361524.
  • 85
    Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15: 336877.
  • 86
    Ghalib R, Levine C, Hassan M, et al. Recombinant human Interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37: 116571.
  • 87
    Mendenhall CL, Shakir AR, Zoiss EA, et al. Thrombocytopenia (T) in patients with chronic hepatitis C: management with Interleukin 11. Gastroenterology 2003; 124 (Suppl.): A770.
  • 88
    Artz AS, Ershler WB, Rustgi V. Interleukin-11 for thrombocytopenia associated with hepatitis C. J Clin Gastroenterol 2001; 33: 4256.
  • 89
    Ustun C, Dainer PM, Faguet GB. Interleukin-11 administration normalizes the platelet count in a hypersplenic cirrhotic patient. Ann Hematol 2002; 81: 60910.
  • 90
    Lawitz EJ, Hepburn MJ, Casey TJ. A pilot study of Interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 2004; 99: 16.
    Direct Link:
  • 91
    Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100: 345769.
  • 92
    Dessypiris E, Graber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 1988; 72: 20602.
  • 93
    Cosman D. The hematopoietin receptor superfamily. Cytokine 1993; 5: 95106.
  • 94
    Abraham PA, Halstenson CE, Macres MM, et al. Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies. Clin Pharmacol Ther 1992; 52: 20513.
  • 95
    Pirisi M, Fabris C, Soardo G, Cecchin E, Toniutto P, Bartoli E. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 1994; 21: 37680.
  • 96
    Homoncik M, Jilma-Stohlawetz P, Schmidt M, Ferlitsch A, Peck-Radosavljevic M. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomised, double blind, placebo-controlled study. Aliment Pharmacol Ther 2004; 20: 17.
  • 97
    Gergely AF, Lafarge P, Fouchard-Hubert I, Lunel-Fabiana F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002; 35: 12812.
  • 98
    Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 24919.
  • 99
    Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 130211.
  • 100
    Spiegel BM, Chen K, Chiou CF, Robbins S, Younossi ZM. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005; 3: 103442.